Physician profile
Walter Thomas
NPI 1952379463
$5,863.63
in general payments reported to CMS, 2019-2025
29 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $606 · 2021: $926 · 2022: $730 · 2023: $975 · 2024: $1,061 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,379.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,690.50 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $442.40 | 2019-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $420.95 | 2020-2024 | Rexulti, Abilify Mycite |
| Janssen Pharmaceuticals, INC | $369.04 | 2022-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.45 | 2022-2025 | Caplyta |
| Saxum Surgical, INC. | $339.68 | 2024-2025 | |
| Lundbeck LLC | $321.97 | 2020-2024 | Rexulti |
| Amgen INC. | $317.22 | 2019-2025 | Repatha |
| Indivior INC. | $282.78 | 2020-2025 | Sublocade |
| Allergan, INC. | $220.62 | 2020 | |
| Axsome Therapeutics, INC. | $186.74 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $180.25 | 2024-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $118.33 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $116.14 | 2022-2023 | Mounjaro |
| Alkermes, INC. | $84.64 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $65.79 | 2021 | |
| Merck Sharp & Dohme LLC | $54.41 | 2021-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $53.79 | 2021-2022 | |
| Bausch Health US, LLC | $42.83 | 2023 | Wellbutrin, Aplenzin |
| Gilead Sciences, INC. | $33.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.11 | 2022 | |
| Glaxosmithkline, LLC. | $26.07 | 2024 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $23.18 | 2022 | |
| Novo Nordisk INC | $22.49 | 2025 | |
| Exact Sciences Corporation | $18.76 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.16 | 2019 | |
| Corium, LLC | $13.24 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.96 | 2019 | |
| Orexo US, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.